Gold prices steady near $3,400/oz as Sept rate cut bets rise; econ. data awaited
James William Rogers, the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), recently executed significant stock sales, according to a new SEC filing. The company, currently valued at $7.88 billion, has seen its stock surge 42% year-to-date despite recent volatility. On March 18, Rogers sold a total of 23,030 shares of Class A common stock, generating approximately $1.06 million. The transactions were conducted at prices ranging from $45.78 to $47.40 per share.
These sales were made under a pre-established Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling stocks. Following these transactions, Rogers holds 164,750 shares directly. The company demonstrates solid liquidity with a current ratio of 2.29 and has achieved impressive revenue growth of 30% in the last twelve months.
In other recent news, Tempus AI has reported a strong performance in its fourth-quarter earnings for 2024, with a 35.8% increase in revenue year-over-year, totaling $700 million. Despite this growth, the company posted a negative earnings per share of -0.18. Tempus AI has also raised its 2025 revenue guidance to approximately $1.24 billion, factoring in contributions from its recent acquisition of Ambry Genetics. This acquisition is expected to enhance Tempus’s capabilities in AI-driven research platforms, expanding its reach in the healthcare sector.
On the analyst front, JPMorgan has downgraded Tempus AI’s stock from Overweight to Neutral, while increasing the price target to $55.00, citing a fully valued stock relative to peers. Meanwhile, Stifel has maintained its Hold rating on Tempus AI, with a reiterated price target of $65.00, noting the company’s robust revenue growth and fair market valuation compared to industry standards.
In addition to these financial updates, Tempus AI has announced the acquisition of Deep 6 AI, a company specializing in using AI to streamline clinical trials. This acquisition aims to broaden Tempus’s network and enhance its applications, such as those assisting in clinical trial matching and care gap addressing. These developments reflect Tempus AI’s strategic direction as it continues to expand its influence in the healthcare technology landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.